The White House will announce ‌a drug ​pricing deal with Regeneron Pharmaceuticals on Thursday, ⁠according to a ​source familiar with the matter.

Regeneron ⁠is the sole drugmaker among 17 large pharmaceutical companies ‌that received ​letters from President Donald ‌Trump in July ‌that was left to sign such an ⁠agreement.

The company ‌did not ⁠immediately respond to ⁠Reuters' ⁠request for comment.

Shares of the company ‌were up more than 2% in morning trading.